Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: AMCR Institute
Location: 625 W Citracado Pkwy Suite 112 Escondido CA, 92025 
Principal Investigator: Timothy S. Bailey, MD

Background

According to the American Diabetes Association (ADA), about 1.25 million Americans have Type 1 diabetes. Type 1 diabetes is a chronic condition wherein the pancreas produces low to no insulin. Insulin is a hormone that the body needs to allow sugar (glucose) to enter the cells to produce energy. The ADA estimates that each year, about 40,000 Americans will be diagnosed with Type 1 diabetes.

Since a Type 1 does not receive sufficient insulin, he/she would need to receive multiple daily injections (MDI). This study seeks to compare two marketed insulins in terms of glucose values in target range in individuals with Type 1 diabetes.

This study seeks adults aged 18 to 70 years old who are diagnosed with Type 1 diabetes. Participants are required to attend all study visits at the research site for over the period of 12 weeks. Through participating in this research you may help develop a more effective and efficient treatment for Type 1 diabetes in the future.

Why Participate? 

• You may experience improvements to your Type 1 diabetes management.
• You may receive the study medication (insulin) provided at no cost to you throughout the duration of the study.
• You may help develop a more effective and efficient type of Type 1 diabetes treatment.
• You may be compensated for time and travel. There are no out of pocket expenses. No insurance required.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health care professionals will monitor your health as it relates to the study.

Who Can Participate?

• Adults aged 18 to 70 years old who have Type 1 diabetes.
• Must be treated with Multiple Daily Injections (MDI) (use basal and rapid acting insulin analogs )/once daily basal insulin injection.
• Able to attend up to 8 study visits at the research site for over the period of 12 weeks.
• Available for up to 12 phone calls with the study team over the duration of the study